Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.03
- Piotroski Score 4.00
- Grade Buy
- Symbol (ISUN)
- Company iSun, Inc.
- Price $0.05
- Changes Percentage (-31.33%)
- Change -$0.02
- Day Low $0.03
- Day High $0.07
- Year High $12.80
iSun, Inc. operates as a solar engineering, construction, and procurement contractor for commercial and industrial customers in the Northeastern United States. It also provides electrical contracting services; and data and communication services. The company was formerly known as The Peck Company Holdings, Inc. and changed its name to iSun, Inc. in January 2021. iSun, Inc. was founded in 1972 and is headquartered in South Burlington, Vermont.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.73
- Trailing P/E Ratio -0.06
- Forward P/E Ratio -0.06
- P/E Growth -0.06
- Net Income $-19,417,000
Income Statement
Quarterly
Annual
Latest News of ISUN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Factcheckers often 'young kids' who misunderstand experts, Prof Anne Twomey tells inquiry - video
Prof Anne Twomey highlights that social media platforms delegate fact-checking to inexperienced individuals, leading to misinterpretation of expert opinions. This can result in inaccurate decisions on...
By The Guardian | 1 week ago -
UK's NICE Says Alzheimer's Disease Drug Kisunla Is Not Cost-Effective
The UK approved the Alzheimer's drug Kisunla, facing reimbursement challenges due to cost. NICE requires cost-effective benefits for NHS reimbursement. Kisunla targets beta amyloid and tau plaque in t...
By Forbes | 2 weeks ago -
Feds 'misunderstand the law,' Mayor Adams claims as he tries to toss...
Eric Adams' lawyers argue against federal prosecutors' bribery charges, claiming they misinterpret the law. Defense attorney Alex Spiro contends that the allegations lack evidence of illegal activity,...
By New York Post | 3 weeks ago
